Research reviewed by Gram suggests that boosting a protein called Netrin-3 may reduce fatty liver disease in mice. In a 2026 study, mice with diet-induced fatty liver disease that received Netrin-3 showed less liver fat, lower blood sugar, and healthier liver enzymes by activating a fat-burning pathway called AMPK-PPARα. Human benefits remain untested.

According to research reviewed by Gram, a protein called Netrin-3 may help protect the liver from fatty liver disease, at least in mice. Fatty liver disease, now called MAFLD, occurs when fat builds up in the liver and can lead to lasting damage. In this study, researchers fed mice a high-fat diet to trigger the condition. They found that levels of Netrin-3 and a partner protein, UNC5A, were lower than normal in both the blood and the liver. When the scientists gave the mice extra Netrin-3, the animals gained less weight, had better blood sugar and blood fat levels, showed less fat in the liver, and had healthier liver enzyme readings. The protein appeared to work by switching on AMPK, a cell energy sensor that helps the liver burn fat instead of storing it. Because the work was done in mice and lab cells, it does not yet show whether people would benefit. It does point to Netrin-3 as a possible future treatment.

Key Statistics

A 2026 study published in Archives of Physiology and Biochemistry found that treating mice with high-fat diet-induced fatty liver disease with Netrin-3 reduced body weight, liver fat, and markers of liver injury.

In the same 2026 mouse study, blocking the energy sensor AMPK with Compound C reversed the protective effects of Netrin-3, which supports AMPK as a key pathway in the treatment’s action.

The Quick Take

  • What they studied: Scientists wanted to know whether a protein called Netrin-3 could slow or reverse fatty liver disease, and how it might do so inside liver cells.
  • Who participated: The main experiments used laboratory mice that were fed a high-fat diet to cause fatty liver disease. Additional experiments used a line of mouse liver cells grown in the lab. The number of animals was not reported in the summary available.
  • Key finding: Mice with fatty liver disease had lower levels of Netrin-3. When they received Netrin-3, they showed less weight gain, less liver fat, better blood sugar and blood fat levels, and less liver injury. The protein appeared to work by activating a cell energy pathway that helps burn fat.
  • What it means for you: This is early laboratory and animal research, so it cannot yet tell you whether Netrin-3 will help people. Proven steps such as healthy eating, regular physical activity, weight management, and limiting alcohol remain the best-established ways to protect your liver.

The Research Details

Researchers first created fatty liver disease in mice by feeding them a high-fat diet. This approach mimics how the condition often develops in people who eat large amounts of fat and calories over time. They then measured Netrin-3 and UNC5A levels in the blood and liver to see whether these proteins changed as the disease progressed.

Next, the team gave some of the sick mice recombinant Netrin-3, which is a lab-made version of the natural protein. Some mice also received a compound called Compound C, which blocks AMPK, a cell energy switch. This allowed the researchers to test whether the benefits depended on that pathway. They tracked body weight, body fat, cholesterol and fat levels in the blood, blood sugar, insulin, liver enzymes that signal damage, and the amount of fat stored in liver tissue.

Finally, the team used mouse liver cells, called AML12 cells, that were loaded with extra fatty acids to mimic fat overload. They treated these cells with Netrin-3, with Compound C, or with a tool that silences the AMPKα gene. Testing the same idea in both whole animals and isolated cells helps show whether an effect is direct, which strengthens the case for the proposed mechanism.

Using both living animals and cells allowed the researchers to see the full picture of what happens in a body and also to pinpoint the cell pathway responsible. If Netrin-3 helped in the animals but not in the cells, the cells would not explain the result. Blocking AMPK with Compound C and with gene silencing produced the same pattern, which makes the pathway explanation more convincing.

The study used several complementary methods, including blood tests, tissue analysis, and cell experiments, and it included control conditions such as blocking the proposed pathway. These features make the results more credible. However, the summary available does not report how many mice or how many cell experiments were used, and it does not list statistical details. Animal studies also do not always translate to people, so results should be viewed as preliminary. The journal’s impact factor was not confirmed for this assessment.

What the Results Show

The researchers found that Netrin-3 and its partner protein UNC5A were both reduced in mice with fatty liver disease. This suggests the body’s natural levels of this protein may fall as the condition develops, although the study does not prove that low Netrin-3 causes the disease.

When mice received Netrin-3, several markers of health improved. Their body weight and body fat decreased. Blood fat levels, blood sugar, and insulin levels also moved toward healthier ranges. Liver enzymes called ALT and AST, which rise when the liver is injured, came down, and the amount of fat stored in the liver was reduced. Together, these changes suggest the treatment eased both the metabolic problems and the liver damage linked to the condition.

The researchers also looked at what was happening inside the liver. Netrin-3 increased the activity of AMPK and ACC, two proteins involved in controlling how the body handles fat. It also restored the levels of PPARα, Fabp1, and CPT1α, which are proteins that help cells break down fatty acids for energy. In simple terms, the liver appeared to switch from storing fat to burning it.

The most telling result came from the blocking experiments. When Compound C was given along with Netrin-3, most of the protective effects disappeared in the mice. In the liver cells, blocking AMPK with Compound C or with a gene-silencing tool canceled the boost in AMPK and ACC signaling that Netrin-3 had produced. This pattern supports the idea that AMPK is a key link in how Netrin-3 works.

Beyond liver fat, the researchers observed improvements in several whole-body measures, including body weight, body fat, blood fat levels, and blood sugar. These findings matter because fatty liver disease is closely tied to metabolic problems such as weight gain, high blood sugar, and high insulin, so treatments that address the whole picture may be especially valuable. The changes in liver enzymes also suggest the protein may protect liver cells from injury, not only reduce fat.

Fatty liver disease is widely linked to excess fat intake, weight gain, and insulin resistance, and AMPK is already known as a central regulator of energy use in cells. This study adds a new piece to that picture by identifying Netrin-3, a protein better known for guiding nerve cells during development, as a possible regulator of liver fat burning. Currently, lifestyle changes such as weight loss and exercise remain the main recommended approach, and no drug targeting Netrin-3 is approved. Results like these are usually the first step in drug discovery, which typically requires much more testing before any human use.

The most important limitation is that the study was done in mice and in laboratory cells. Human liver disease is more complex, and a protein that works well in mice can behave differently in people. The summary also does not report the number of animals or cell experiments, and it does not describe how long the treatment lasted or whether there were any side effects. Because the research used a recombinant, lab-made form of the protein, it is not yet clear how a treatment would be delivered or how safe it would be over the long term. Finally, the findings come from one study, and independent teams will need to confirm them before stronger conclusions can be drawn.

The Bottom Line

Based on this study alone, the evidence is preliminary. Confidence that Netrin-3 helps fatty liver disease in mice is moderate, since the results were consistent across animal and cell experiments. Confidence that it would work the same way in people is currently low because no human trials have been reported. No one should change medical treatment based on this study. The most established recommendations, with high confidence, remain losing excess weight, eating a balanced diet low in added sugars and refined carbohydrates, staying physically active, and limiting alcohol.

People with fatty liver disease, clinicians who treat liver and metabolic conditions, and researchers looking for new drug targets should pay attention to this work. Individuals who are generally healthy and do not have fatty liver disease do not need to act on these findings. Anyone with a diagnosis should keep following the advice of their doctor rather than seeking unapproved protein supplements or treatments.

Discoveries like this usually take many years to reach patients. Typically, a promising molecule must first be tested for safety and dosing in additional animal studies, then in small human trials, and then in larger trials before it could be approved. Realistically, any benefit for people would be a long way off, and no near-term change in care should be expected from this single study.

Frequently Asked Questions

Can Netrin-3 treat fatty liver disease?

Netrin-3 remains experimental. Research reviewed by Gram found that it reduced fatty liver disease in mice fed a high-fat diet, including less liver fat and better liver enzyme levels. Human trials have not been reported, so it is a candidate therapy under study rather than an approved treatment.

What is MAFLD and how is it different from fatty liver disease?

MAFLD, or metabolic dysfunction-associated fatty liver disease, is a condition in which excess fat builds up in the liver. It is closely tied to metabolic health issues such as weight gain, high blood sugar, and insulin resistance. The newer name highlights these metabolic links and can progress to inflammation and injury of the liver.

How does Netrin-3 help the liver burn fat?

In mouse and liver cell experiments, Netrin-3 activated AMPK, a cellular energy sensor. This increased PPARα and related genes such as CPT1α, which help cells break down fatty acids for energy. Blocking AMPK with Compound C or gene silencing canceled the benefit, supporting that pathway as the mechanism.

What steps help reduce fatty liver disease right now?

Current guidance focuses on losing excess weight, often around 5 to 10 percent of body weight for people with excess weight, limiting added sugars and alcohol, and exercising regularly. This Netrin-3 study did not test these steps, but they remain the best-established approach. Talk with your doctor before making major changes.

Want to Apply This Research?

  • Track your body weight once per week at the same time of day, and log your waist measurement monthly. If your doctor has tested your liver enzymes or liver fat, record those results when you receive them so you can see trends over time.
  • Use the app to set one specific goal, such as swapping sugary drinks for water or unsweetened tea on most days, or adding a 20 to 30 minute walk on at least four days per week. Log each completed goal so you can see your consistency build over several weeks.
  • Review your weekly weight, activity, and diet logs every month to spot patterns. Share these summaries with your healthcare provider at routine visits, since they can combine them with blood test results. Update your tracking if your doctor recommends new targets, and watch for future research updates on Netrin-3 that may change what is recommended.

This article summarizes an early laboratory and animal study and is for general information only. The research was conducted in mice and in cultured liver cells, and it has not been tested in people. It is not medical advice and should not be used to diagnose, treat, or prevent any condition. If you have fatty liver disease or concerns about your liver, consult a qualified healthcare professional before making changes to your diet, exercise, supplements, or medications.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Netrin-3 attenuates metabolic dysfunction-associated fatty liver disease by activating the AMPK-PPARα axis. , Archives of physiology and biochemistry (2026). PubMed 43043069 | DOI
Topics
Netrin-3 fatty liver disease MAFLD AMPK PPARα liver fat fatty acid oxidation metabolic health